Arginine and the microcirculation

Citation for published version (APA):

Document status and date:
Published: 01/01/2015

Document Version:
Publisher's PDF, also known as Version of record

Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher’s website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 10 Mar. 2020
In the following paragraphs we will describe the value is of our work for society and the economy. Furthermore, we will highlight which target population will benefit from our newly developed model and therapeutic strategy. Finally we will shortly describe the innovation of our model and the utilization of our knowledge.

Social and economic value of the current thesis

Sepsis is a major health problem, which are associated with high rates of morbidity and mortality. The reported incidence varies between 75 to 300 per 100,000 patients worldwide [1], with mortality rates of approximately 25%. However, if complicated by multiple organ failure due to an impaired microcirculation, the mortality rates doubles [2]. This results in high socio-economic costs. As described in chapter 2 of this thesis, an imbalance in NO production by NOS3 and NOS2 is hypothesized to play a key role in the development of multiple organ failure during sepsis and inflammatory conditions [3,4]. Therefore, restoring NO production from arginine by the proper cells and enzymes in these conditions has been the subject of numerous studies over the past decades [5-14]. Thus far, there is no definite treatment, so that the search for good therapeutic interventions is still ongoing. Previous nutritional interventions focussed on arginine supplementation, but the outcomes of these treatments differed widely [14-25], with either increased [21], unchanged [9,14,19], or decreased morbidity and mortality.

The disparate outcomes of the human studies appear to result from the experimental animal models used to simulate and treat sepsis. Thus far, the acute sepsis model, which takes only a few hours, is usually used, but this model does not cause arginine deficiency. Therefore, the first goal of the current thesis was the development of an experimental model that mimics the human arginine-deficient state during endotoxemia. As described in detail in Chapter 4, we developed a mouse model with an 18h infusion of endotoxin that causes a decreased arginine availability and a diminished NO production and decreased microcirculation in jejunial tissue as found in septic human patients. Since our model mimics the human situation better with respect to the functional arginine deficiency than previously used models, new interventions tested in this model may
be better suitable to have outcomes that better predict efficacy in humans that the previously used acute models.

To develop a new therapeutic approach for sepsis, we first investigated whether arginine would be a suitable substrate in our model. As hypothesized, the results of our study show that arginine supplementation did not restore arginine availability and microcirculation during endotoxemia. Therefore, we conclude that arginine is not a suitable substrate for the treatment of these disturbances in NO production.

In this thesis we further showed that L-citrulline supplementation is a good therapeutic strategy to restore the arginine availability in the cells of the jejunum during experimental endotoxemia. L-citrulline supplementation even resulted in an improved microcirculation and maintenance of the gastro-intestinal barrier in healthy athletes. Based on these beneficial results of L-citrulline supplementation, the findings during our study are potentially of high social and economic value for the medical society and the world of sports.

**Target population**

The results of this thesis are of interest to several target groups within the research field and health care. At first, the results presented in this thesis provide new insights for the development of specific nutritional supplements for patients with a disturbed arginine metabolism, such as septic patients. Therefore, the data of thesis may be of special interest to pharmaceutical companies to develop new nutritional formulas for clinical usage in patients with disturbances in arginine metabolism. In line these results are important for health care workers in the field of intensive care medicine, which deal with these septic patients daily. However, this arginine deficiency is not only present in inflammatory conditions, but is also present in abnormal fracture healing [26], disturbed wound healing [27] and cardiovascular diseases [28-30]. Therefore, the results of this thesis, will be of interest to a much broader audience, including surgeons, cardiologists, and investigators in the biomedical field with special interest in endothelial dysfunction and microcirculation. Also, athletes and investigators in the field of sport medicine are likely to be interested, based on the beneficial results of L-citrulline supplementation during strenuous exercise.
Knowledge utilization

The knowledge obtained from our research in the area of nutritional supplementation in patients with arginine deficiency will be valorized through its application in future studies focused on improved metabolism during inflammatory conditions. The knowledge received from this thesis can already be incorporated in the current standard treatment of critical ill patients, focusing on enhancement of the microcirculation. Furthermore, as already mentioned in the previous paragraph the insights from our studies will help to develop nutritional strategies targeting the endothelial function in several different pathophysiological states. This eventually will lead to a less social economic cost based on a decreased hospitalization and diminished morbidity and mortality.

Innovation

The search for a good therapeutic strategy to maintain a functional microcirculation during sepsis and endotoxemia has been the subject of many different studies over the past decades. However, experimental studies used acute sepsis models, which are not a reliable model to study the human situation. In this regard, the present thesis exhibits various novel findings and insights. First, the experimental model described in this thesis is the first model, which uses a prolonged endotoxemia to test the therapeutic strategies targeting the arginine availability and metabolism. Furthermore, our results are the first to show that citrulline is a suitable substrate to improve arginine availability and microcirculatory function during inflammatory conditions, and, therefore, may be a promising new therapeutic strategy in patients. The novelty of the model and therapeutic approach has not gone unnoticed, as we were awarded the International Sepsis Forum award of the European Society of Intensive Care Medicine (ESICM) in 2010 for the best new research on therapeutic interventions in the treatment of human sepsis. These studies will serve as basis for future studies that address arginine and NO deficiencies in human patients, especially in the (critically) ill.
References

citating the microcirculation in sepsis: the central role of nitric oxide, emerging
concepts for novel therapies, and challenges for clinical trials. Acad Emerg Med 15:
399-413.
circulatory perfusion derangements in patients with severe sepsis and septic shock:
relationship to hemodynamics, oxygen transport, and survival. Ann Emerg Med 49:
88-98, 98 e81-82.
5. Bruins MJ (2001) L-Arginine treatment during acute and longterm endotoxemia in
the pig: effects on jejunal motility and interorgan protein, arginine and nitric oxide
metabolism 1-243.
in pigs decreases liver protein turnover and increases hindquarter protein turnover
both during and after endotoxemia. Am J Clin Nutr 75: 1031-1044.
mentation in hyperdynamic endotoxemic pigs: effect on nitric oxide synthesis by
the different organs. Crit Care Med 30: 508-517.
arginine pretreatment on nitric oxide metabolism and hepatosplanchnic perfusion
shock increases nitric oxide production without haemodynamic instability. Clin Sci
and sepsis. JPEN J Parenter Enteral Nutr 29: S70-74.
discussion 336-337.


